Sanofi

Global investment firm CD&R on Monday announced an open offer to acquire a 26 per cent stake in Sanofi Consumer Healthcare India Ltd for an aggregate of up to Rs 2,983 crore. The development follows Sanofi and Clayton, Dubilier & Rice (CD&R) entering into exclusive negotiations whereby CD&R Group has agreed to acquire a controlling stake in Opella, which holds a 60.4 per cent stake in Sanofi Consumer Healthcare India. The offer is made at a price of Rs 4,982.05 per share, aggregating to a total consideration of up to Rs 2,983.23 crore, according to the offer letter by Citigroup Global Markets India, the manager of the transaction, shared on BSE by Sanofi Consumer Healthcare India. The open offer has been triggered by Sanofi and CD&R entering into exclusive negotiations for the potential sale and purchase of a 50 per cent controlling stake in Opella, Sanofi's consumer healthcare division. The valuation of Opella is based on an enterprise value of 16 billion ...

The Hyderabad facility is expected to do a significant amount of documentation work related to drug clinical trials, Roach added

Novavax said it would co-commercialize its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza combination vaccines using Novavax's Matrix-M adjuvant

Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including Frisium, a leading anti-epileptic drug

Drug firm Sanofi India on Thursday said its net profit increased by 2.5 per cent to Rs 123 crore for the second quarter ended on June 30, 2023. The company reported a net profit of Rs 120 crore in the April-June quarter of last year. Revenue from operations rose to Rs 706 crore in the period under review from Rs 699 crore in the same period last year, Sanofi India said in a regulatory filing. The company follows a January-December financial year. "The company has delivered a strong second quarter performance despite the National List of Essential Medicines (NLEM) impact," Sanofi India Managing Director Rodolfo Hrosz said. The company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its established and innovative products in India, he added.

CLOSING BELL: The fag-end rally was powered by IndusInd Bank, Bajaj Finance, Tata Motors, Reliance Industries, HDFC Bank, Maruti Suzuki, and Bajaj Finserv

Sanofi added its "bold" decision to go without earlier-stage clinical COPD trials had shaved years off the development time

The drugmaker is offering voluntary retirement scheme (VRS) to all its employees at two sites near Hyderabad

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Drug firm Sanofi India on Thursday reported a net profit of Rs 131 crore for the third quarter ended September 2022. The company had posted a net profit of Rs 530 crore in the July-September quarter of last year, the company said in a regulatory filing. The drug firm follows a January-December financial year. Revenue from operations stood at Rs 692 crore in the period under review. The same stood at Rs 754 crore in the corresponding period previous year. The company said the results of the September quarter were not comparable with the same quarter last year as it had transferred its nutraceuticals business to Universal Nutriscience, enabling a gain of Rs 489 crore.

Sanofi fell 13% on Thursday, taking its 2-day decline to 20%; GSK slid 6.9%

The companies point to the risk of new variants and waning immunity that could lead to an increase in demand for additional booster shots in some populations.

Sanofi-GSK's shot relies on a conventional protein-based approach, compared with the newer mRNA technology used in established Covid-19 vaccines from Pfizer-BioNTech and Moderna

Will also acquire other legacy associated brands such as Sofradex (antibacterial cream), Sofracort (eye and ear drops), Soframycin-Tulle (cream) for India and Sri Lanka markets

French drugmaker Sanofi said Tuesday it was shelving plans for a Covid-19 vaccine based on messenger RNA despite positive results from early stage testing

The pharmaceutical giant, which has lagged rivals in deploying technology behind some of the world's top-selling Covid shots, made the decision despite positive results in phase one and two trials

German biotech firm CureVac earlier this month also acknowledged rivals' dominance

Sanofi has lagged behind upstarts BioNTech SE and Moderna Inc. in the pandemic as they raced ahead with mRNA shots that have now been injected into arms more than a billion times

Semglee may now be substituted for Sanofi's Lantus by a pharmacist in the US

India part of 35,000 volunteer global efficacy trial